In Vitro Screening for Hepatic Metastasis Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective identification of new CRC disease-associated hepatic genes as molecular biomarkers for monitoring liver involvement in CRC, assessing metastasis development, and discovering therapies targeting these genes in patients with and without colorectal cancer.
Innovation Solution
An in vitro method is developed to screen agents modulating hepatic metastasis by inhibiting specific gene groups, using a primary mix-culture of hepatic cells exposed to CRC-derived factors, measuring gene expression levels before and after agent exposure, and comparing these levels to determine inhibitory effects on prometastatic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional screening methods are used to identify hepatic genes associated with CRC metastasis, then the process is simple and quick, but the identification precision and reliability of biomarkers are insufficient
Solution Approach 1:
The screening method is divided into multiple sequential steps: (1) obtaining primary hepatic cells from patient biopsies, (2) exposing cells to CRC-derived soluble factors, (3) measuring gene expression levels using RNA sequencing, (4) comparing expression levels between exposed and control groups, and (5) identifying differentially expressed genes. This segmentation allows each step to be optimized independently, achieving high precision without overwhelming complexity.
Solution Approach 2:
The method performs preliminary actions by first obtaining patient-specific hepatic cells and pre-exposing them to CRC-derived factors before conducting the actual gene expression analysis. This preliminary preparation ensures that the cells are in the appropriate physiological state for accurate biomarker identification, improving measurement precision while maintaining manageable complexity through structured workflow.
2Difficulty of detecting and measuring
If comprehensive gene expression analysis is performed on hepatic tissues, then the detection capability for metastasis-related genes is improved, but the time and resources required increase
Solution Approach 1:
CRC-derived soluble factors serve as intermediaries that mediate the interaction between CRC cells and hepatic cells. By exposing hepatic cells to these pre-characterized factors, the method indirectly activates metastasis-related pathways without requiring direct co-culture of CRC and hepatic cells. This intermediary approach enhances detection capability while reducing the complexity and time of experimental setup.
Solution Approach 2:
The method changes key parameters by using patient-specific hepatic cells instead of universal cell lines, and by measuring relative gene expression changes rather than absolute levels. This allows the detection system to adapt to individual patient variations, improving detection capability for patient-specific biomarkers while maintaining a standardized workflow that controls time investment.
3Adaptability or versatility
If patient-specific hepatic cells are used for screening, then the adaptability to individual patient conditions is improved, but the ease of operation and standardization decrease
Solution Approach 1:
The method achieves universality by using a standardized protocol that can be applied to any patient's hepatic cells. The core workflow—obtaining cells, exposing to CRC factors, measuring gene expression, and analyzing differential expression—remains consistent across all patients. This universal framework maintains ease of operation while accommodating patient-specific variations through the use of individual patient cells and personalized data analysis.
Solution Approach 2:
The method incorporates feedback by comparing gene expression levels in patient-specific cells against control groups and using the results to identify patient-specific biomarkers. This feedback loop allows the system to adapt to individual patient conditions while maintaining a structured, repeatable process. The standardized analysis pipeline provides feedback mechanisms that guide interpretation of patient-specific data without requiring custom procedures for each patient.
Data Source
AI summary
An in vitro method to discover or screen various an agent capable of modulating onset or progression of hepatic metastasis through inhibition or suppression of genes associated with prometastatic reaction in hepatic tissue. The method comprises preparing a primary mix-culture of hepatic parenchymal and non-parenchymal cells, exposing cells to colorectal cancer cells to induce a prometastatic reaction; the exposing the cells to the therapeutic agent to be screened, and then measuring gene expression profiles of cells exposed to the agent, and finally comparing the measured gene expression profile to a reference gene expression profile whereby to determine if the agent has a positive effect on inhibiting or suppressing metastatic reaction. Also disclosed is an array of compositions to identify an agent comprising an antisense oligonucleotide capable of treating a colorectal cancer patient each having a nucleotide sequence that hybridizes with group 1 genes (PRDX4, CRP, ID1, MT1E, TNFSF14, MRC1, ICAM1, IL18, IL10, TFN) and/or group 2 genes (NGF, EPHA1, ERBB2IP, SDC1, COL18A1, KNG1, ADH1B, CYP2E1).